Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Inclusion Criteria: * Patients with recurrent and/or metastatic nasopharyngeal carcinoma, which is not feasible for curative therapy. * Patients must have histologically or cytologically confirmed NPC with Epstein-Barr Encoded RNA (EBER) positive tumour cells and/or elevated serum EBV DNA viral titres. * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan, MRI, or calipers by clinical exam. * No more than 1 line of previous chemotherapy and/or targeted therapy or patients who do not tolerate chemotherapy. Pts who progress within 1 year of chemoradiation for locally advanced disease are allowed on study. * Age \> 21. In Taiwan, patients with who are older than 20 years old are eligible * Life expectancy \> 3 months * Eastern Cooperative Oncology Group (ECOG) 0-1 * Patients must have normal organ and marrow function as defined below: * White Blood Cells (WBC) ≥ 2000/μL * Neutrophils ≥ 1500/μL * Platelets ≥ 100 x10\*\*3/μL * Hemoglobin \> 9.0 g/dL * Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN) or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below): * Female CrCl = \[(140 - age in years) x weight in kg x 0.85\] ÷ (72 x serum creatinine in mg/dL) * Male CrCl = \[(140 - age in years) x …